CA2436311A1 - Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda - Google Patents

Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda Download PDF

Info

Publication number
CA2436311A1
CA2436311A1 CA002436311A CA2436311A CA2436311A1 CA 2436311 A1 CA2436311 A1 CA 2436311A1 CA 002436311 A CA002436311 A CA 002436311A CA 2436311 A CA2436311 A CA 2436311A CA 2436311 A1 CA2436311 A1 CA 2436311A1
Authority
CA
Canada
Prior art keywords
nmda receptor
receptor antagonist
day
human patient
antagonist compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002436311A
Other languages
English (en)
Inventor
Stuart Lipton M.D.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adamas Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2436311A1 publication Critical patent/CA2436311A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions et des méthodes de traitement d'un patient humain atteint d'un trouble neuropsychiatrique. L'invention concerne plus particulièrement des compositions et des méthodes qui modulent ou antagonisent l'activité des récepteurs neuronaux de NMDA. Cette activité antagoniste peut moduler la réaction excitatrice des neurones induite par le glutamate, ce qui inhibe un effet excitotoxique, produit un effet neurotrophique, et induit un effet thérapeutique pouvant traiter le trouble neuropsychiatrique.
CA002436311A 2000-12-07 2001-12-07 Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda Abandoned CA2436311A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25400700P 2000-12-07 2000-12-07
US60/254,007 2000-12-07
PCT/US2001/048516 WO2002045710A1 (fr) 2000-12-07 2001-12-07 Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda

Publications (1)

Publication Number Publication Date
CA2436311A1 true CA2436311A1 (fr) 2002-06-13

Family

ID=22962564

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002436311A Abandoned CA2436311A1 (fr) 2000-12-07 2001-12-07 Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda

Country Status (8)

Country Link
EP (1) EP1351670A4 (fr)
JP (1) JP2004515477A (fr)
CN (1) CN1486180A (fr)
AU (1) AU2002229056A1 (fr)
BR (1) BR0116001A (fr)
CA (1) CA2436311A1 (fr)
MX (1) MXPA03005130A (fr)
WO (1) WO2002045710A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8500795B2 (en) 1999-08-09 2013-08-06 Cardiokinetix, Inc. Retrievable devices for improving cardiac function
US10307147B2 (en) 1999-08-09 2019-06-04 Edwards Lifesciences Corporation System for improving cardiac function by sealing a partitioning membrane within a ventricle
US8377114B2 (en) 1999-08-09 2013-02-19 Cardiokinetix, Inc. Sealing and filling ventricular partitioning devices to improve cardiac function
US8257428B2 (en) 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US7674222B2 (en) 1999-08-09 2010-03-09 Cardiokinetix, Inc. Cardiac device and methods of use thereof
US9694121B2 (en) 1999-08-09 2017-07-04 Cardiokinetix, Inc. Systems and methods for improving cardiac function
US8529430B2 (en) 2002-08-01 2013-09-10 Cardiokinetix, Inc. Therapeutic methods and devices following myocardial infarction
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US9078660B2 (en) 2000-08-09 2015-07-14 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US9332993B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US10064696B2 (en) 2000-08-09 2018-09-04 Edwards Lifesciences Corporation Devices and methods for delivering an endocardial device
US9332992B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Method for making a laminar ventricular partitioning device
TW200403066A (en) * 2002-04-30 2004-03-01 Novartis Ag New uses of substituted aminoalkanephosphonic acids
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
JP2008503475A (ja) 2004-06-17 2008-02-07 フォーレスト ラボラトリーズ， インコーポレイテッド メマンチンの放出が改変された製剤
EA013474B1 (ru) * 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
EP1986735A4 (fr) 2006-02-06 2011-06-29 Northwind Ventures Systèmes et procédés de réduction de volume
ES2690205T3 (es) * 2006-04-13 2018-11-19 Neurotech Pharmaceuticals Co., Ltd. Composición farmacéutica para tratar o prevenir enfermedades inflamatorias
RU2401263C2 (ru) * 2008-09-10 2010-10-10 Государственное образовательное учреждение высшего профессионального образования Самарский государственный технический университет Аминопроизводные адамантана, обладающие противовирусной активностью в отношении вируса гриппа
IT1396556B1 (it) 2009-02-11 2012-12-14 Serra Uso di memantina per il trattamento di disturbi dell umore
CN102070463A (zh) * 2009-06-11 2011-05-25 辽宁利锋科技开发有限公司 具有金刚烷结构药物美金刚胺及其衍生物和类似物抗肿瘤新适应症的应用
AU2010315535A1 (en) 2009-10-26 2012-05-03 Cardiokinetix, Inc. Ventricular volume reduction
AU2010325960C1 (en) 2009-12-02 2015-08-06 Adamas Pharma, Llc Amantadine compositions and methods of use
JP5562716B2 (ja) * 2010-05-12 2014-07-30 花王株式会社 電位依存性カチオンチャネル抑制剤
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CA2946153C (fr) * 2014-04-30 2022-06-14 Yufeng Jane Tseng Utilisation de composes connus comme inhibiteurs de d-acide amine oxydase (daao)
CN118239847A (zh) * 2014-05-29 2024-06-25 广州喜鹊医药有限公司 具有神经保护作用的金刚烷胺硝酸酯化合物的制备方法
CA2962747C (fr) 2014-09-28 2023-02-28 Cardiokinetix, Inc. Appareils permettant de traiter un dysfonctionnement cardiaque
JP2018521007A (ja) * 2015-05-22 2018-08-02 ヴィスタゲン セラピューティクス、インコーポレイテッド Ｌ−４−クロロキヌレニンの治療的使用
DE102018107407A1 (de) 2017-03-28 2018-10-04 Edwards Lifesciences Corporation Positionieren, einsetzen und zurückholen von implantierbaren vorrichtungen
US11529319B2 (en) * 2017-08-01 2022-12-20 Stuart A. Lipton Methods and compositions for treating neurological conditions
JP7543136B2 (ja) * 2017-11-22 2024-09-02 パノラマ リサーチ，インコーポレイティド Ｃｎｓ疾患を治療するためのアミノアダマンチルナイトレート化合物およびそれらの使用
CN109206317B (zh) * 2018-09-12 2021-07-09 青岛海蓝医药有限公司 一种金刚烷胺类硝酸酯衍生物的制备工艺
CN110938006A (zh) * 2019-12-04 2020-03-31 重庆植恩药业有限公司 盐酸美金刚杂质c的制备方法
CN114544826B (zh) * 2020-11-24 2023-12-08 重庆医科大学 检测血浆中组氨酸的试剂在制备抑郁症检测试剂盒中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS584718A (ja) * 1981-06-30 1983-01-11 Nippon Chibagaigii Kk 新規適応症に用うる医薬製剤
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents

Also Published As

Publication number Publication date
WO2002045710A1 (fr) 2002-06-13
CN1486180A (zh) 2004-03-31
EP1351670A4 (fr) 2004-07-07
EP1351670A1 (fr) 2003-10-15
WO2002045710A9 (fr) 2003-04-24
BR0116001A (pt) 2004-07-06
AU2002229056A1 (en) 2002-06-18
JP2004515477A (ja) 2004-05-27
MXPA03005130A (es) 2004-12-06

Similar Documents

Publication Publication Date Title
US20100137448A1 (en) Methods for Treating Neuropsychiatric Disorders with NMDA Receptor Antagonists
WO2002045710A1 (fr) Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda
Weinstock et al. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer’s disease
Birkmayer et al. Parkinson’s disease: Biochemistry, clinical pathology, and treatment
US20060270742A1 (en) Compositions and methods for the treatment of neurodegenerative diseases
US20120156139A1 (en) Isotopically labeled neurochemical agents and uses therof for diagnosing conditions and disorders
Zhou et al. Protective role of taurine against morphine-induced neurotoxicity in C6 cells via inhibition of oxidative stress
JP2024516421A (ja) Ｍｄｍａ鏡像異性体
TW200808696A (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
JP2007513169A (ja) 自殺傾向を予防しまたは減少させるための、および自殺傾向に関連する大うつ病を治療するためのメマンチン
US20140371229A1 (en) New therapeutic approaches for treating parkinson's disease
RU2630583C2 (ru) Аналоги цистамина, применяемые для лечения болезни паркинсона
NZ509231A (en) Use of GABA analogs to treat insomnia
JP2009501224A (ja) 神経保護の方法
US20050096395A1 (en) Methods of treating attention deficit/hyperactivity disorder (adhd)
AU2741600A (en) Method for the treatment of incontinence
AU2006235400A1 (en) Method of treating schizophrenia prodrome
EP1852113A2 (fr) Methodes pour le traitement des maladies neuropsychiatriques avec des antagonistes du recepteur
AU2007203426B2 (en) Methods for treating neuropsychiatric disorders with NMDA receptor antagonists
Piletz et al. Putative agmatinase inhibitor for hypoxic-ischemic new born brain damage
Matveychuk et al. Comparison of phenelzine and geometric isomers of its active metabolite, β-phenylethylidenehydrazine, on rat brain levels of amino acids, biogenic amine neurotransmitters and methylamine
CA2631623A1 (fr) Inhibiteurs de la kynurenine aminotransferase et applications
Gmiro et al. Comparison of the Antiparkinson Activity of Levodopa, Memantine, and Guanidine-Containing Analogs of Amantadine and Memantine (IEM-2151 and IEM-2163) in Rats with Rotenone-Induced Parkinsonism
JP2008540458A (ja) 治療活性を有するダイヤモンドイド誘導体
Vender et al. MonthlyUpdate—Central & Peripheral Nervous Systems: Pharmacotherapeutic Potential for Compounds Acting at NMDA Receptors: Update 1995

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead